View our 2024 Program – 2025 coming soon!
| Thursday, October 24th | |
|---|---|
| 16:30-17:00 | Tisagenlecleucel in relapsed/refractory Follicular Lymphoma – Update and 3 year RWE Industry supported Meet the Expert Session |
| 17:00-17:15 | Technical Break |
| 17:15-17:45 | CMV prophylaxis to treatment: update and current data 2024 Industry-supported Meet the Expert Session |
| 17:45-18:00 | Technical Break |
| 18:00-18:30 | ECP and Ruxolitinib combination in severe steroid-refractory acute GvHD Industry-supported Meet the Expert Session |
| Friday, October 25th | |
|---|---|
| 08:00-08:15 | Good Morning Coffee |
| 08:15-08:30 | Welcome Note Congress Co-Chairs |
| 08:30-10:00 | Session 1: Graft-versus-host disease (GvHD) Prophylaxis and Treatment |
| Controversy: Is Post-transplant cyclophosphamide (PTCy) or anti-thymocyte globulin (ATG) the current standard for GvHD prophylaxis in matched unrelated transplant? | |
| Moderator: Nicolaus Kröger, Germany | |
| 08:30-08:45 | PTCy: Leo Luznik, USA |
| 08:45-09:00 | ATG: Takanori Teshima, Japan |
| Controversy: Is Axatilimab becoming the new standard for chronic cGvHD? | |
| Moderator: Arnon Nagler, Israel | |
| 09:00-09:15 | Yes: Stephanie Lee, USA |
| 09:15-09:30 | No: Corey Cutler, USA |
| 09:30-10:00 | Panel discussion: All session faculty |
| 10:00-10:20 | Coffee Break, Poster Viewing and Visit Exhibition |
| 10:20-11:50 | Targeting inflammation and fibrosis from the start – can belumosudil improve long-term outcomes in chronic GvHD? Industry-supported Symposium |
| 11:50-12:00 | Technical Break |
| 12:00-13:30 | Session 2: Acute Myeloid Leukemia (AML) |
| Controversy: Should 5-Azacitidine venetoclax-based induction replace 7+3 induction in AML 50-65 years of age? | |
| Moderator: Andreas Burchert, Germany | |
| 12:00-12:15 | Yes: Thomas Schroeder, Germany |
| 12:15-12:30 | No: Lars Bullinger, Germany |
| Controversy: Should all patients with FMS‐like tyrosine kinase 3 (FLT3)-positive AML receive maintenance therapy post-allograft? | |
| Moderator: Lars Bullinger, Germany | |
| 12:30-12:45 | Yes: Andreas Burchert, Germany |
| 12:45-13:00 | No: Arnon Nagler, Israel |
| 13:00-13:30 | Panel discussion: All session faculty |
| 13:30-14:15 | Lunch Break, Poster Viewing and Visit Exhibition |
| 14:15-15:15 | Controversy: Should all patients with FLT3-positive AML go to transplant? Industry-supported Lunch Symposium |
| 15:15-15:30 | Short Break |
| 15:30-17:00 | Session 3: Acute Lymphoblastic Leukemia (ALL) |
| Controversy: Should we include short-course blinatumomab in adult ALL patients with minimal residual disease (MRD) pre allogeneic stem cell transplantation (allo-SCT)? | |
| Moderator: Matthias Stelljes, Germany | |
| 15:30-15:45 | Yes: Nicola Gökbuget, Germany |
| 15:45-16:00 | No: Sebastian Giebel, Poland |
| Controversy: Are we ready for total body irradiation (TBI)-free conditioning in adult ALL | |
| Moderator: Sebastian Giebel, Poland | |
| 16:00-16:15 | Yes: Avichai Shimoni, Israel |
| 16:15-16:30 | No: Matthias Stelljes, Germany |
| 16:30-17:00 | Panel discussion: All session faculty |
| 17:00-17:30 | Coffee Break, Poster Viewing and Visit Exhibition |
| 17:30-19:00 | Session 4: Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) |
| Controversy: Are we ready for molecular prognostication for transplant decision-making in MDS? | |
| Moderator: Nicolaus Kröger, Germany | |
| 17:30-17:45 | Yes: Carmelo Gurnari, Italy |
| 17:45-18:00 | No: Fernando Barroso Duarte, Brazil |
| Controversy: Are we ready for molecular prognostication for transplant decision-making in MPN? | |
| Moderator: Avichai Shimoni, Israel | |
| 18:00-18:15 | Yes: Nico Gagelmann, Germany |
| 18:15-18:30 | No: Donal McLornan, UK |
| 18:30-19:00 | Panel discussion: All session faculty |
| Saturday, October 26th | |
|---|---|
| 08:30-10:00 | Session 5: Lymphoma and Myeloma |
| Controversy: Can we replace autologous stem-cell transplantation (auto-SCT) for multiple myeloma by CAR T or bispecific antibodies? | |
| Moderator: TBA | |
| 08:30-08:45 | Yes: Suzanne Lentzsch, USA |
| 08:45-09:00 | No: Maximilian Merz, Germany |
| Controversy: Do we abandon allo-SCT for Non-Hodgkin’s lymphoma? | |
| Moderator: Nico Gagelmann, Germany | |
| 09:00-09:15 | Yes: Anna Sureda, Spain |
| 09:15-09:30 | No: Ali Bazarbachi, Lebanon |
| 09:30-10:00 | Panel discussion: All session faculty |
| 10:00-10:30 | Coffee Break, Poster Viewing and Visit Exhibition |
| 10:30-12:00 | Session 6: GvHD Prevention and Treatment |
| Controversy: Is abatacept the new standard for matched and mismatched unrelated donor SCT? | |
| Moderator: Corey Cutler, USA | |
| 10:30-10:45 | Yes: Robert Soiffer, USA |
| 10:45-11:00 | No: Francesca Bonifazi, Italy |
| Controversy: Are mesenchymal stem cells (MSCs) an alternative to ruxolitinib in SR GvHD? |
|
| Moderator: Francis Ayuk, Germany | |
| 11:00-11:15 | Yes: Peter Bader, Germany |
| 11:15-11:30 | No: Hildegard Greinix, Austria |
| 11:30-12:00 | Panel discussion: All session faculty |
| 12:00-12:45 | Lunch Break, Poster Viewing and Visit Exhibition |
| 12:45-14:15 | Advancements in CMV-management post HSCT Industry-supported Lunch Symposium |
| 14:15-14:30 | Short Break |
| 14:30-16:00 | Session 7: Non-malignancies |
| Controversy: Are we ready for haploidentical stem cell transplantation (haplo-SCT) up front as routine practice in severe aplastic anemia (SAA)? | |
| Moderator: Emanuele Angelucci, Italy | |
| 14:30-14:45 | Yes: Carlo Dufour, Italy |
| 14:45-15:00 | No: Antonio Risitano, Italy |
| Controversy: Haplo-SCT vs gene therapy in sickle cell disease (SCD) | |
| Moderator: Franco Locatelli, Italy | |
| 15:00-15:15 | Haplo-SCT: Emanuele Angelucci, Italy |
| 15:15-15:30 | Gene therapy: Markus Mapara, USA |
| 15:30-16:00 | Panel discussion: All session faculty |
| 16:00-16:30 | Coffee Break, Poster Viewing and Visit Exhibition |
| 16:30-17:30 | Session 8: Myths and Facts around EBV post HSCT |
| A series of statements and disucssion Moderator: Jan Styczynski, Poland |
|
| 16:30-16:40 | Statement: There is a threshold for EBV PCR in blood starting treatment with Anti CD20 antibodies Facts, presented by: Marcos de Lima, USA |
| 16:40-16:50 | Statement: EBV specific T cells are the treatment of choice for EBV reactivation and EBV related PTLD Facts, presented by: Guenther Koehne, USA |
| 16:50-17:00 | Statement: EBV serostatus predicts outcome after allogeneic HSCT Facts, presented by: Jan Styczynski, Poland |
| 17:00-17:30 | Panel discussion: All session faculty |
| 17:30-17:45 | Short Break |
| 17:45-19:15 | Session 9: Pediatrics |
| Controversy: Do we need allogeneic HSCT consolidation after CD19 CAR T therapy for pediatric ALL? |
|
| Moderator: Krzysztof Kalwak, Poland | |
| 17:45-18:00 | Yes: Peihua Lu, China |
| 18:00-18:15 | No: André Baruchel, France |
| Controversy: αβ T cells T cell depletion haplo-SCT vs non T cell depletion haplo-SCT in pediatric malignancies | |
| Moderator: Emanuele Angelucci, Italy | |
| 18:15-18:30 | αβ T cells T cell depletion: Franco Locatelli, Italy |
| 18:30-18:45 | Non T cell depletion: Krzysztof Kalwak, Poland |
| 18:45-19:15 | Panel discussion: All session faculty |
| 19:15 | Poster Walk and Awards Session (Poster Area) |
| Sunday, October 27th | |
|---|---|
| 09:00-10:30 | Session 10: Artificial Intelligence (AI) and Specific Cell Therapy |
| Controversy: Are we ready for prediction of transplant-related complication including GvHD by machine-learning and AI? |
|
| Moderator: Alessandro Rambaldi, Italy | |
| 09:00-09:15 | Yes: Roni Shouval, USA |
| 09:15-09:30 | No: Francis Ayuk, Germany |
| 09:30-09:45 | Discussion |
| Controversy: Will cytotoxic T lymphocytes (CTLs) become a standard option for post-transplant infection? |
|
| Moderator: Lori Muffly, USA | |
| 09:45-10:00 | Yes: Britta Eiz-Vesper, Germany |
| 10:00-10:15 | No: Rafael de la Cámara, Spain |
| 10:15-10:30 | Discussion |
| 10:30-11:00 | Coffee Break |
| 11:00-12:30 | Session 11: Graft Manipulation and Autoimmune Diseases |
| Controversy: Are we back to graft manipulation in allogeneic transplantation? |
|
| Moderator: Nicolaus Kröger, Germany | |
| 11:00-11:15 | Yes: Lori Muffly, USA |
| 11:15-11:30 | No: Alessandro Rambaldi, Italy |
| 11:30-11:45 | Discussion |
| Controversy: Do CAR T cells replace autologous SCT in autoimmune disease? |
|
| Moderator: Arnon Nagler, Israel | |
| 11:45-12:00 | Yes: Fabian Müller, Germany |
| 12:00-12:15 | No: Raffaella Greco, Italy |
| 12:15-12:30 | Discussion |
| 12:30 | Closing Remarks Congress Co-Chairs |
